SEA BCMA
Alternative Names: SEA-BCMA; SGN-BCMALatest Information Update: 15 Dec 2023
At a glance
- Originator Seattle Genetics
- Developer Seagen
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Multiple myeloma
Most Recent Events
- 14 Dec 2023 Seagen has been acquired by Pfizer
- 29 Nov 2023 Seagen terminates a phase I trial in Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA (IV) due to portfolio prioritization (NCT03582033)
- 29 Nov 2023 Seagen terminates a phase I trial in Multiple myeloma (Second-line therapy or greater) in USA (IV) due to portfolio prioritization (NCT03582033)